Chemotherapy combined with bevacizumab is a common choice for patients with metastatic colorectal cancer (mCRC). Unfortunately, the benefit is rather limited and it has so far not been possible to identify patients likely to benefit from this regimen. Candidate biomarkers should reflect the anti-angiogenic effect of therapies, preferentially at an early stage during treatment, and be obtainable through minimal invasive procedures.

MicroRNAs are short non-coding single-stranded RNAs that regulate protein translation ([@bib5]; [@bib6]; [@bib13]). Though exerting their functions in the intracellular compartment, miRNAs have also been identified in several extracellular compartments ([@bib2]; [@bib18]; [@bib29]). Circulating extracellular miRNAs are stable in body fluids presumably due to their incorporation in exosomes/microvesicles or protein complexes, protecting them from degradation by endogenous RNase activity ([@bib18]; [@bib14]). Evidence suggests that these small vesicles act as mediators of intercellular communications ([@bib3]) through the transfer of mRNA and miRNAs from the vesicles to the recipient cells ([@bib26]). Circulating miRNAs are also detectable in patients with colorectal cancer (CRC; [@bib2]). The clinical importance of circulating miRNAs as biomarkers of CRC ([@bib21]), and pointers as to presence or absence of metastatic disease ([@bib27]), are currently under investigation. The role of circulating miRNAs as predictive biomarkers in patients with CRC in general, and of the effect of anti-angiogenic therapies specifically, is largely unknown.

MicroRNA-126 has a high endothelial cell (EC) specificity ([@bib30]; [@bib32]). It is involved in EC proliferation, migration, survival, and in the regulation of blood vessel integrity ([@bib8]; [@bib28]). Shortly after demonstrating the content of miRNAs in small vesicles released from human cells ([@bib26]), miRNA-126 was also shown to be contained in the plasma exosomes/microvesicles in healthy individuals, and a fraction of these originated from ECs ([@bib11]). Circulating miRNA-126 (cir-miRNA-126) in microvesicles/exosomes is able to induce angiogenesis in neighbouring ECs using a paracrine mechanism by fusing with the cell membrane of the target ECs ([@bib19]).

Bevacizumab is an antibody involved in targeting the vascular endothelial growth factor A (VEGF-A). It prevents the binding of VEGF-A to the receptor (VEGFR-2), which is a main mediator of angiogenic signalling ([@bib7]). The signalling cascade initiated by the binding of VEGF-A to VEGFR-2, is regulated by miRNA-126 ([@bib8]; [@bib28]). Microvesicles are released from healthy as well as damaged cells, and elevated levels of EC-derived microvesicles have been correlated with vascular damage ([@bib1]). Considering this and the fact that miRNA-126 is highly specific for ECs, it is likely that cir-miRNA-126 reflects EC turnover. In patients with mCRC treated with anti-angiogenic drugs, changes in cir-miRNA-126 during treatment may therefore serve as a biomarker of bevacizumab (anti-VEGF-A) efficacy.

The aim of the current study was to analyse the predictive value of cir-miRNA-126 during first-line chemotherapy and bevacizumab in patients with mCRC.

Materials and methods
=====================

Reporting in this study is in accordance with the REMARK ([@bib17]) and BRISQUE ([@bib20]) criteria.

Patients and study treatment
----------------------------

This study consecutively included untreated patients with histologically verified mCRC planned for first-line chemotherapy (XELOX) combined with bevacizumab, with an overall aim of identifying predictive biomarkers. All patients were screened for eligibility and inclusion was possible for 68 ([Figure 1](#fig1){ref-type="fig"}) in the inclusion phase from March 2010 through March 2013. All patients were \>18 years and presented with normal hepatic, renal, and bone marrow function. Previous malignancies diagnosed within 5 years (except non-melanoma skin cancer and carcinoma *in situ* of the cervical uterus) were the exclusion criteria.

Chemotherapy consisted of capecitabine 1000 mg m^−2^ twice daily on days 1 through 14 (28 doses) of a 21-day cycle and oxaliplatin 130 mg m^−2^ as a 2-hour intravenous infusion on day 1. Bevacizumab was given as an infusion (7.5 mg kg^−1^) on day 1 of each treatment cycle. Treatment was continued until disease progression or unacceptable toxicity, but treatment-free intervals were accepted after six cycles, if requested by the patient.

All data were recorded according to good clinical practice. The study was approved by the Regional Scientific Ethical Committee and the Danish Data Protection Agency (S-20100005), and informed consent was obtained from all patients enrolled in the study.

Evaluation of treatment efficacy
--------------------------------

Response rates (RR) were assessed according to the Response Evaluation Criteria In Solid Tumours (RECIST 1.1; [@bib4]). Evaluations were based on clinical and radiologic examination using CT scans of the chest and abdomen. Responding patients were classified as having complete response (CR) or partial response (PR), whereas non-responding patients were classified as stable disease (SD) or progressive disease (PD).

Blood samples
-------------

Sampling of peripheral blood was carried out before treatment (baseline) and at each clinical evaluation (after every 3 weeks) until progression. To standardise the comparability, three time points (baseline, first clinical evaluation after 3 weeks, and progression) were chosen for the present study. Blood samples were available for analysis at baseline for all 68 patients (100%), at first clinical evaluation in 63 patients (93%), and at progression in 47 patients (69%).

Venous blood was drawn from the antecubital area and collected in 6 ml EDTA-containing tubes, spun down for 10 min. at 2500 **g**, and plasma was transferred to Greiner tubes (Sigma-Aldrich, St Louis, MO, USA) and frozen immediately at −80 °C. The median storage time from sampling to analysis was 2.1 years. Samples were transported on ice from storage for analysis.

miRNA-126 analyses
------------------

Analyses of miRNA-126 were performed by staff who were unaware of the patient outcome.

Total RNA purification kit (Norgen Biotek Corp., Thorold, ON, Canada) was used to purify RNA from 100 *μ*l of each plasma sample according to the manufacturer\'s instructions with small modifications: 10 m[M]{.smallcaps} dithiothreitol (Sigma-Aldrich Co. LLC, Steinheim, Germany) and 1.7 pM synthetic *C. elegans* miR-54 and -238 (TAG Copenhagen A/S, Denmark) were added into the lysis buffer. RNAse inhibitor (1 *μ*l) (20 U *μ*l^−1^, Applied Biosystems, Foster city, CA, USA) was added to every elution tube before eluting RNA. Purified RNA was kept at −20 °C before being used for reverse transcription.

Reverse transcription was performed using the TaqMan microRNA Reverse Transcription Kit (Applied Biosystems) according to the instructions by the manufacturer with modifications. The reverse transcription reaction volume was 15 *μ*l using 1.5 *μ*l Multiscribe reverse transcriptase, 3 *μ*l RT-primer-mix (hsa-miRNA-126-3p, cel-miRNA-54, and cel-miRNA-238), 1.5 *μ*l 10 X buffer, 0.3 *μ*l 100 m[M]{.smallcaps} dNTPs, 0.23 *μ*l RNAse inhibitor, and 8.47 *μ*l RNA purified from plasma. Reverse transcription was performed on an ABI 2720 Thermal Cycler (Applied Biosystems) using a standard protocol (16 °C, 30 min; 42 °C, 30 min; 85 °C, 5 min; hold at 4 °C). Reverse-transcribed samples were kept at −20 °C until used.

Reliable and reproducible measurement of circulating miRNA is hampered by the fact that no endogenous miRNA can be used for reliable normalisation, and the amount of total RNA purified from plasma is so small (the concentration of RNA in eluates is typically ⩽5 ng *μ*l^−1^) that it is not readily quantified by UV-absorbance measurements. In the absence of absolute determination of miR-126 copy number by interpolation to standard curves, which was not possible in this study, we standardised our miRNA amounts based on fixed plasma sample volumes and used spiked-in synthetic non-mammalian miRNA to account for technical variation. This approach enables the comparison of the relative levels of miR-126 between the samples.

cDNA samples and three TaqMan microRNA ( × 20) assays (hsa-miRNA-126-3p, cel-miRNA-54 and cel-miRNA-238; Applied Biosystems) were applied to six 384-well plates according to the manufacturer\'s instructions. All miR-assays were performed in triplicate (coefficient of variation, 3.6%). Real-time PCR reaction volume was 10 *μ*l for each reaction. Each reaction contained 0.5 *μ*l × 20 TaqMan microRNA assay, 5 *μ*l × 2 TaqMan Universal PCR Master mix, no AmpErase UNG, 3.5 *μ*l nuclease-free H~2~O, and 1 *μ*l cDNA. The real-time PCR was performed in the ViiA7 real-time PCR system (Applied Biosystems) using the standard 384-well protocol (50 °C, 2 min; 95 °C, 10 min; 40 cycles of 95 °C for 15 s, and 60 °C for 60 s; hold at 4 °C). Data processing took place using the Applied Biosystems\' ViiA7 real-time PCR analysis software (v.1.2.2). This approach provides an estimate of the total amount of stable miRNA-126 in a sample. Thus, it is not possible to determine whether the miRNA originates from microvessicles or miRNA-protein complexes.

In the 384-well plate data analysis the highly reliable auto detectors setting (auto threshold and auto baseline) was chosen for data from all six plates. The average Cq value of hsa- miRNA-126-3p was subtracted from the average Cq values of Cel-miRNA-54 and cel-miRNA-238 for that particular sample yielding the −ΔCq (Cq of cel-miRNAs−Cq of hsa-miRNA-126-3p) values. The −ΔCq values were normalised by the average of −ΔCq values from the whole data set. The normalised −ΔΔCq values were used in the further analyses after transformation according to the 2−ΔΔCq method ([@bib23]). The presented estimates for cir-miRNA-126 are thus relative values without a dimension.

Statistics
----------

We report median values with a 95% confidence interval (CI) and mean values ±s.d. The comparisons of medians were performed using Wilcoxon rank-sum test and means using an equal-variance *t*-test. Fisher\'s exact test was used for comparison among categorical parameters. Correlations between continuous variables were quantified using linear regression analyses. Survival functions were estimated by log-rank tests and illustrated by the Kaplan--Meier method. Progression-free survival (PFS) was defined as the time from start of treatment until the first documented tumour progression or death from any cause. The PFS data were censored in 10 cases. Six patients underwent liver resections, two had their primary tumours removed, and two patients underwent radio frequency ablation for liver and lung metastases, respectively. Data were censored from the day of the intervention. All patients were successfully followed until progression. All statistical calculations were carried out using the NCSS statistical software (NCSS Statistical Software, Kaysville, UT, USA, version 2007). *P* values\<0.05 were considered significant, and all tests were two-sided.

Results
=======

Patient characteristics
-----------------------

On the based of the initial screening, 68 patients were available for analyses ([Figure 1](#fig1){ref-type="fig"}).

Patient characteristics and baseline cir-miRNA-126 levels are shown in [Table 1](#tbl1){ref-type="table"}. A significantly higher baseline cir-miRNA-126 level in the younger half of the patients was demonstrated.

Response to treatment
---------------------

Three patients stopped treatment early before evaluation and two patients did not have evaluable lesions (too small in size) according to RECIST ([Figure 1](#fig1){ref-type="fig"}) and were thus excluded from the response and PFS comparisons.

The mean cir-miRNA-126 level at baseline, first clinical evaluation (after 3 weeks of treatment), and at progression according to treatment response is shown in [Figure 2](#fig2){ref-type="fig"}. Four patients had PD (tumour progression of minimum 20%), 28 SD (\<30% tumour regression and \<20% progression), 29 PR (tumour regression of minimum 30%), and 2 CR (no visible tumours). There were no significant differences between the mean cir-miRNA-126 levels in the four response groups at baseline and first evaluation. The changes in cir-miRNA-126 during treatment, however, suggested different patterns associated with treatment response. This is illustrated in [Figure 3](#fig3){ref-type="fig"} focusing on the changes from baseline to first clinical evaluation after 3 weeks in non-responding (PD+SD) and responding patients (PR+CR), respectively. Among the non-responding patients, 25 out of the 32 had an increase in cir-miRNA-126 levels compared with 12 out of the 31 responding patients, *P*=0.002. Accordingly, the median change in cir-miRNA-126 levels for the non-responding patients was 0.244 (95% CI, 0.050--0.565) compared with a median change of −0.374 (95% CI, −0.472 to 0.111) in the responding patients, *P*=0.002. Similarly, addressing the changes from baseline to progression, 20 out of the 26 non-responding patients had an increase in cir-miRNA-126 levels compared with 3 out of 21 responding patients, *P*\<10^−4^. Accordingly, the median change in cir-miRNA-126 levels for the non-responding patients was 0.288 (95% CI, 0.042--0.507) compared with a median change of −0.524 (95% CI, −0.848 to 0.173) in the responding patients, *P*=0.0002.

Further, a positive significant relationship was documented by comparing the changes in tumour size with the corresponding changes in cir-miRNA-126 levels, *r*=0.48, *P*=0.0001 ([Figure 4](#fig4){ref-type="fig"}).

There was no significant relationship between age and treatment efficacy.

Survival analyses
-----------------

Grouping patients according to the median cir-miRNA-126 level at baseline resulted in a significant separation of the PFS curves ([Figure 5A](#fig5){ref-type="fig"}) favouring patients with miRNA-126 levels above the median (median PFS 9.3 months, 95% CI 8.8--10.6 months) compared with patients with miRNA-126 levels below the median (median PFS 7.3 months (95% CI 6.7--9.2 months), hazard ratio (HR) 0.53 (95% CI, 0.29--0.97), *P*=0.02.

Grouping patients according to the changes in miRNA-126 levels from baseline to first clinical evaluation resulted in a similar, but non-significant separation of the PFS curves ([Figure 5B](#fig5){ref-type="fig"}) favouring patients with decreasing miRNA-126 levels (median PFS 9.2 months, 95% CI 7.3--10.6 months) compared with patients with increasing miRNA-126 levels (median PFS 8.8 months (95% CI 6.7--9.3 months), HR 0.60 (95% CI, 0.33--1.09), *P*=0.07.

Discussion
==========

We analysed cir-miRNA-126 in patients with mCRC treated with first-line chemotherapy combined with bevacizumab and argue for a relationship between tumour response and changes in cir-miRNA-126 levels.

The results documented a relationship between increasing levels of cir-miRNA-126 and a lack of benefit from the treatment, whereas decreasing levels of cir-miRNA-126 were associated with treatment benefit. It is worth noticing that the non-responding patients seem to present with a rather uniform change in cir-miRNA-126 levels, in that 5 of the 7 patients with decreasing levels only had a minor decrease ([Figure 3](#fig3){ref-type="fig"}). Thus, 30 out of the 32 non-responding patients exhibited stable or increasing cir-miRNA-126 levels. We are not aware of similar studies in patients with mCRC but [@bib25] analysed circulating miRNAs, including cir-miRNA-126, in 21 patients with uveal melanoma treated with adjuvant dacarbazine and interferon-*α*-2b . They documented changes in cir-miRNA-126 during treatment but no association with outcome. [@bib16] demonstrated an association between high levels of circulating EC and worse RR to first-line chemotherapy+bevacizumab in 99 patients with mCRC . In another setting, [@bib31] demonstrated that patients with rectal cancer treated with neoadjuvant radiotherapy, chemotherapy, and bevacizumab with elevated levels of circulating ECs had a worse outcome . The results from the present study thus agree with the previous reports on the correlation between increasing levels of circulating ECs and vascular damage ([@bib1]). The results from these two studies of patients with CRC may thus reflect a similar mechanism as the one addressed in the present study.

An attempt to explain the possible relationship between the changes in cir-miRNA-126 and tumour response may require consideration of the normalisation hypothesis by [@bib12]. Part of this hypothesis addresses the consequences of too potent/high doses of anti-angiogenic therapy. In such cases, the vessel pruning may become excessive causing necrosis and hypoxia, hampering delivery of drugs such as chemotherapeutics. With the specificity of miRNA-126 for the EC compartment and the established relationship between the increased levels of circulating microvesicles and vascular damage ([@bib1]), the increasing cir-miRNA-126 levels in the present study may reflect an EC-damage associated with bevacizumab treatment. Microvesicles containing miRNA-126 released in response to tissue damage have been shown to induce angiogenesis in recipient cells ([@bib15]), and the increasing levels of cir-miRNA-126 may also reflect bevacizumab resistance leading to renewed stimulation of angiogenesis. Selective release from the tumour-associated blood vessels of the tumour suppressive miRNA-126 ([@bib22]) may constitute a third explanation.

In line with the relationship between cir-miRNA-126 levels and RR, we also detected an association with the actual changes in tumour size during treatment (percent change of predefined target lesions from baseline to first evaluation). This illustration of data primarily served as a visual presentation of the proposed link between treatment efficacy (changes in tumour size) and cir-miRNA-126. Furthermore, it demonstrates that the presented relationship between the two parameters was not just a consequence of the arbitrary cutoffs defined in the RECIST criteria.

Our present results suggest a favourable prognosis in patients with high levels of cir-miRNA-126 at baseline and in patients with decreasing cir-miRNA-126 levels during treatment. These observations are comparable to our previous studies in patients with mCRC based on the analysis of miRNA-126 in tumour tissue ([@bib10], [@bib9]). Similar to our results, the relationship between circulating EC and RR in the study by [@bib16] did not translate into a convincing relationship with PFS. In the present study, this may partly be due to a rather high rate of surgical interventions towards the metastatic and primary tumour lesions (15%), causing these well-responding patients to contribute with limited time for the PFS analyses due to censoring. A recent study of 45 patients with malignant mesothelioma by [@bib24] demonstrated a similar association between low levels of circulating miRNA-126 and a worse prognosis .

So why was baseline cir-miRNA-126 related to PFS and not RR, although changes in cir-miRNA-126 were related to RR and not convincingly to PFS? A possible explanation for this divergence may be provided, if we address cir-miRNA-126 as two independent biomarkers in the two different specific situations (baseline and changes). Baseline cir-miRNA-126 is the result of/influenced by an untreated tumour burden and does not necessarily have anything to do with the treatment intended to be used. The relationship with PFS in this case may thus indicate a pure prognostic value. Changes in cir-miRNA-126, on the other hand, is the consequence of the delivered chemotherapy and bevacizumab and thus reflects an entirely different situation where treatment responsiveness, blood vessel vulnerability and the angiogenic balance in the patient may be the primary mediators of miRNA-126 to the circulation, thus indicating a possible predictive value.

Apart from a possible connection between age and cir-miRNA-126 levels there were no significant relationships between patient characteristics and baseline levels to suggest an overall patient and tumour-independent relationship between cir-miRNA-126 and treatment outcome. This is comparable to our previous studies ([@bib10], [@bib9]) indicating no relationship between miRNA-126 and patient/tumour characteristics.

In conclusion, the current findings suggest a relationship between early changes in cir-miRNA-126 during first-line chemotherapy+bevacizumab and tumour response in patients with mCRC. This may represent a new predictive biomarker of resistance to anti-angiogenic containing therapies and deserves further research.
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![**Consort diagram of the study population.**](bjc2014652f1){#fig1}

![**Mean cir-miRNA-126 (cir-miRNA-126) levels according to treatment response (PD, SD, PR, and CR).** Horizontal lines mark the respective standard deviation intervals. The broken time line between first clinical evaluation (after 3 weeks) and progression indicates that this time period varies between the patients. As it appears from the overlapping s.d. intervals there were no significant differences between the means of the respective response groups at baseline and first evaluation. The mean cir-miRNA-126 of the PD group was significantly higher than that of the remaining three response groups (*P*\<0.05) at progression. (PD, *N*=4), (SD, *N*=28), (PR, *N*=29), and (CR=2).](bjc2014652f2){#fig2}

![**Changes in cir-miRNA-126 (cir-miRNA-126) levels from baseline to first clinical evaluation (after three weeks) in (A) non-responding patients (*N*=32) and (B) responding patients (*N*=31).** Green and red lines are used to differentiate between the increasing and decreasing miRNA-126 levels, respectively.](bjc2014652f3){#fig3}

![**Linear regression plot illustrating the relationship between changes in tumour size according to RECIST (PD: increase of tumour size\>20% PR: regression of tumour size\>30% SD: not PD or PR; CR: no visible tumour) and the corresponding changes in circulating miRNA-126 (cir-miRNA-126) levels from baseline.**](bjc2014652f4){#fig4}

![**Progression-free survival curves according to circulating miRNA-126 (cir-miRNA-126) levels (A) at baseline (BL) and (B) changes from baseline to first clinical evaluation (BL--FE).** The blue curve in (**A**) represents patients with baseline miRNA-126 levels above the median and the red curve miRNA-126 levels below the median. The red curve in (**B**) represent patient with decreasing miRNA-126 levels from baseline to first clinical evaluation and the blue curve patients with increasing levels.](bjc2014652f5){#fig5}

###### Patient characteristics and baseline cir-miRNA-126 levels, *N*=68

  **Characteristic**                     **Number (%)**   **Cir-miRNA-126** **Median (95% CI)**   ***P*****-value**
  ------------------------------------- ---------------- --------------------------------------- -------------------
  **Gender**                                                                                     
  Male                                      42 (62)               1.055 (0.759--1.338)                  0.80
  Female                                    26 (38)               1.031 (0.754--1.416)                     
  **Age, years**                                                                                 
  Median                                       66                                                          
  Range                                      32--79                                                        
  ⩾66                                       35 (51)               0.966 (0.730--1.047)                **0.04**
  \<66                                      33 (49)               1.329 (0.815--1.435)                     
  **ECOG PS**                                                                                    
  0                                         46 (68)               1.167 (0.958--1.369)                  0.09
  1--2                                      22 (32)               0.894 (0.583--1.131)                     
  **Location of primary tumour**                                                                 
  Colon                                     37 (54)               1.104 (0.841--1.416)                  0.13
  Rectum                                    31 (46)               0.967 (0.619--1.338)                     
  **Primary tumour operated**                                                                    
  Yes                                       22 (32)               1.119 (0.533--1.406)                  0.60
  No                                        46 (68)               1.022 (0.815--1.338)                     
  **Metastatic organ sites**                                                                     
  1                                         30 (44)               1.001 (0.700--1.356)                  0.73
  ⩾2                                        38 (56)               1.112 (0.759--1.364)                     
  **KRAS**[a](#t1-fn2){ref-type="fn"}                                                            
  WT                                        14 (42)               1.143 (0.759--1.652)                  0.06
  Mut                                       19 (58)               1.029 (0.505--1.200)                     

Abbreviations: CI=confidence interval; Cir-miRNA-126=circulating microRNA-126; ECOG PS=Eastern Cooperative Oncology Group Performance Status; KRAS=Kirsten rat sarcoma viral oncogene homolog; Mut=mutated; WT=wild type. Bold values are used to emphasise the significance of the *P*-value (*P*\<0.05).

Not assessed in all patients.
